• 1. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 2. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 3. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 4. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 5. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279

Research Briefing on [2-(4-bromo-1H-pyrazol-1-yl)ethyl](methyl)amine hydrochloride (CAS: 1909337-61-6)

In recent years, the compound [2-(4-bromo-1H-pyrazol-1-yl)ethyl](methyl)amine hydrochloride (CAS: 1909337-61-6) has garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its pyrazole core and bromo substitution, has shown promise in various therapeutic applications, particularly in the modulation of biological targets such as kinases and GPCRs. The hydrochloride salt form enhances its solubility and bioavailability, making it a valuable candidate for further development.

Recent studies have focused on the synthesis and optimization of this compound, aiming to improve its pharmacological properties. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel synthetic route that increases yield and purity while reducing production costs. The study highlighted the compound's potential as a precursor for more complex molecules in drug discovery pipelines, particularly in oncology and neurology.

Pharmacological evaluations of [2-(4-bromo-1H-pyrazol-1-yl)ethyl](methyl)amine hydrochloride have revealed its efficacy in inhibiting specific kinase pathways implicated in cancer cell proliferation. In vitro assays demonstrated significant activity against a panel of cancer cell lines, with IC50 values in the low micromolar range. These findings suggest its potential as a lead compound for the development of targeted cancer therapies.

Further research has explored the compound's mechanism of action at the molecular level. Structural studies using X-ray crystallography and molecular docking simulations have provided insights into its binding interactions with key enzymatic targets. These studies underscore the importance of the bromo-pyrazole moiety in mediating high-affinity binding, which could inform the design of next-generation inhibitors.

In addition to its therapeutic potential, [2-(4-bromo-1H-pyrazol-1-yl)ethyl](methyl)amine hydrochloride has been investigated for its utility in chemical biology tools. Its ability to selectively label proteins in live-cell imaging applications has been demonstrated, offering new avenues for studying cellular processes. This dual functionality as both a therapeutic agent and a research tool enhances its value in the pharmaceutical and biotechnology sectors.

Despite these advancements, challenges remain in the clinical translation of this compound. Issues such as metabolic stability and off-target effects need to be addressed through further structural optimization. Ongoing research is focused on derivatizing the core structure to improve these properties while maintaining its biological activity.

In conclusion, [2-(4-bromo-1H-pyrazol-1-yl)ethyl](methyl)amine hydrochloride represents a versatile and promising compound in chemical biology and drug discovery. Its unique structural features and broad applicability make it a subject of continued interest. Future studies will likely explore its potential in combination therapies and its role in addressing unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)